TRAW.NASDAQTraws Pharma, INC

Form 4: Traws Pharma CFO Mark Patrick Guerin Resigns, Ceases Section 16 Reporting

Sentiment:

SEC Form 4 Filing

📋All filings for Traws Pharma, INC
🔒Login to Follow

Mark Patrick Guerin, CFO of Traws Pharma, Inc., resigned effective February 5, 2025, and will no longer be subject to Section 16 reporting requirements.

Summary

  • Mark Patrick Guerin, the Chief Financial Officer of Traws Pharma, Inc., has resigned from his position.
  • The resignation was effective as of February 5, 2025.
  • As a result of his resignation, Guerin will no longer be required to report transactions in Traws Pharma's equity securities under Section 16 of the Securities Exchange Act.
  • This means he will no longer file Form 4 or Form 5 related to his transactions in the company's stock.

Sentiment

Score: 5

Explanation: Neutral announcement regarding a change in executive personnel; no inherent positive or negative implications for the company's financial health.

Industry Context

This announcement is a routine disclosure related to a change in executive leadership. Such filings are common and expected when officers resign from their positions at publicly traded companies.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Financial OfficerMark Patrick Guerin02/05/2025Resignation

Stakeholder Impact

  • Shareholders may be interested in who will replace the departing CFO.
  • Employees may experience some uncertainty during the transition period.

Key Dates

DateDescription
02/05/2025Effective date of Mark Patrick Guerin's resignation as CFO of Traws Pharma, Inc.
02/10/2025Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.